Exabis Library
Welcome to the e-CCO Library!
P367: Significant impact on health care utilization upon implementation of an electronic IBD care management program.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P367: The availability of infliximab trough levels in IBD patients on maintenance therapy deeply impacts therapeutic decision-making
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P367: Vedolizumab and early postoperative complications in non-intestinal surgery: A case-matched analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P367: Weight patterns in biologicals treated Inflammatory bowel disease cohort
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P368 Tofacitinib induction efficiency and intracellular cytokine dynamics in ulcerative colitis: Results from clinical practice
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P368: Persistence of biologic therapy and mapping of sequential biologic use: Results of a single centre cohort with 841 patients treated over 18 years
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P368: Proactive Therapeutic Drug Monitoring is more effective than Conventional Management in Inducing Fecal Calprotectin remission in Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P368: Risk factors for serious infections in elderly patients receiving infliximab and other Crohn’s disease therapies: TREAT™ registry data
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P368: Safety issues of azathioprine in patients with inflammatory bowel disease: clinical experience from a referral center
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P368: The presence of extra-intestinal manifestations is associated with poor prognosis in acute severe ulcerative colitis: A KASID multicenter study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P368: Treatment of inflammatory bowel disease in the elderly
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P368: Vedolizumab in inflammatory bowel disease: a retrospective single-centre study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P369 Mycobacterium tuberculosis infection among patients with inflammatory bowel disease under biologics: experience of Croatian Tertiary Centre
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P369: Do teenager and adult onset Crohn´s disease patients have different outcomes? A Portuguese cohort study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P369: Dual Biologic in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P369: Efficacy of infliximab after failure of subcutaneous anti-TNF agents in patients with ulcerative colitis: A multicentre study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P369: High prevalence of abdominal pain in Crohn's Disease patients of the TRUST study cohort- Is there a connection to inflammatory activity?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P369: Improvement in patient-reported outcomes in 2 Phase 3 studies of tofacitinib in patients with moderately to severely active ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P369: Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P369: The comparative frequency of clostridial infection in patients with ulcerative colitis receiving mesenchymal stromal cells and anti-cytokine therapy
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM